Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia
Open Access
- 7 April 2013
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 24 (7), 1886-1892
- https://doi.org/10.1093/annonc/mdt118
Abstract
Only limited data on the prevalence of iron deficiency (ID) and its correlation with clinical parameters are available in cancer. ID frequently contributes to the pathogenesis of anemia in patients with cancer and may lead to several symptoms such as impaired physical function, weakness and fatigue. Parameters of iron status and clinical parameters were evaluated in 1528 patients with cancer who presented consecutively within a four-month period at our center. One thousand fifty-three patients had solid tumors and 475 hematological malignancies. ID [transferrin saturation (TSAT) < 20%] was noted in 645 (42.6%) of the 1513 patients with TSAT tests available and 500 (33.0%) were anemic. ID rates were highest in pancreatic (63.2%), colorectal (51.9%) and lung cancers (50.7%). Of the 409 iron-deficient patients in whom serum ferritin levels were available additionally to TSAT, 335 (81.9%) presented with functional ID (FID) (TSAT < 20%, serum ferritin ≥30 ng/ml) and 74 (18.1%) with absolute ID. In patients with solid tumors, prevalence of ID correlated with cancer stage at diagnosis (P= 0.001), disease status (P = 0.001) and ECOG performance status (P = 0.005). ID was frequently noted in cancer and was associated with advanced disease, close proximity to cancer therapy, and poor performance status in patients with solid tumors.Keywords
This publication has 19 references indexed in Scilit:
- Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trialsActa Oncologica, 2012
- Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009–2010: The AnemOnHe studyEuropean Journal of Cancer, 2012
- Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentrationBlood, 2011
- A new concept for the differential diagnosis and therapy of anaemia in cancer patientsSupportive Care in Cancer, 2010
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyThe New England Journal of Medicine, 2009
- Assessment of iron status and the role for iron-replacement therapy in anaemic cancer patients under the care of a specialist palliative care unitPalliative Medicine, 2009
- The prevalence of iron deficiency among patients presenting with colorectal cancerColorectal Disease, 2005
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal of Cancer, 2004
- Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized TrialJournal of Clinical Oncology, 2004
- Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trialBMJ, 2003